Technology
Upcoming Earnings
Health

Kezar Life Sciences

$18.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-1.53%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell KZR and other stocks, options, ETFs, and crypto commission-free!

About

Kezar Life Sciences, Inc. develops drugs to revolutionize the treatment of autoimmune disorders. It also discovers and develops new therapies targeting protein homeostasis. Read More The firm specializes in the areas of protein degradation and protein secretion to discover and develop novel therapies for the treatment of serious, unmet medical needs. Its product include KZR-616, a first-in-class selective immunoproteasome inhibitor, has completed testing in healthy volunteers . The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Employees
20
Headquarters
South San Francisco, California
Founded
2015
Market Cap
350.64M
Price-Earnings Ratio
Dividend Yield
Average Volume
76.91K
High Today
$18.27
Low Today
$17.23
Open Price
$18.24
Volume
28.83K
52 Week High
$36.33
52 Week Low
$14.77

Collections

Technology
Upcoming Earnings
Health
Biotechnology
Medical
2018 IPO
US
North America

News

Associated PressMar 5

Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs ...

27

Earnings

-$0.49
-$0.43
-$0.36
-$0.30
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.44 per share
Actual
Expected Today, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.